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Abstract
Background: Several indirect comparison methods, including network meta-analyses (NMAs), using individual
patient data (IPD) have been developed to synthesize evidence from a network of trials. Although IPD indirect
comparisons are published with increasing frequency in health care literature, there is no guidance on selecting the
appropriate methodology and on reporting the methods and results.
Methods: In this paper we examine the methods and reporting of indirect comparison methods using IPD. We
searched MEDLINE, Embase, the Cochrane Library, and CINAHL from inception until October 2014. We included
published and unpublished studies reporting a method, application, or review of indirect comparisons using IPD
and at least three interventions.
Results: We identified 37 papers, including a total of 33 empirical networks. Of these, only 9 (27 %) IPD-NMAs
reported the existence of a study protocol, whereas 3 (9 %) studies mentioned that protocols existed without
providing a reference. The 33 empirical networks included 24 (73 %) IPD-NMAs and 9 (27 %) matching adjusted
indirect comparisons (MAICs). Of the 21 (64 %) networks with at least one closed loop, 19 (90 %) were IPD-NMAs,
13 (68 %) of which evaluated the prerequisite consistency assumption, and only 5 (38 %) of the 13 IPD-NMAs used
statistical approaches. The median number of trials included per network was 10 (IQR 4–19) (IPD-NMA: 15
[IQR 8–20]; MAIC: 2 [IQR 3–5]), and the median number of IPD trials included in a network was 3 (IQR 1–9)
(IPD-NMA: 6 [IQR 2–11]; MAIC: 2 [IQR 1–2]). Half of the networks (17; 52 %) applied Bayesian hierarchical models
(14 one-stage, 1 two-stage, 1 used IPD as an informative prior, 1 unclear-stage), including either IPD alone or with
aggregated data (AD). Models for dichotomous and continuous outcomes were available (IPD alone or combined
with AD), as were models for time-to-event data (IPD combined with AD).
Conclusions: One in three indirect comparison methods modeling IPD adjusted results from different trials to
estimate effects as if they had come from the same, randomized, population. Key methodological and reporting
elements (e.g., evaluation of consistency, existence of study protocol) were often missing from an indirect
comparison paper.
Keywords: Network meta-analysis, Individual participant data, Patient-level data, Multiple treatments meta-analysis,
Knowledge synthesis, Research methods, Scoping review
* Correspondence: triccoa@smh.ca
1Li Ka Shing Knowledge Institute, St. Michael’s Hospital, 209 Victoria Street,
East Building, Toronto, ON M5B 1T8, Canada
4Epidemiology Division, Dalla Lana School of Public Health, University of
Toronto, 155 College Street, 6th floor, Toronto, ON M5T 3M7, Canada
Full list of author information is available at the end of the article
© 2016 Veroniki et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Veroniki et al. BMC Medical Research Methodology  (2016) 16:47 
DOI 10.1186/s12874-016-0146-y
Background
Systematic reviews and meta-analyses using individual pa-
tient data (IPD) aim to obtain, verify, and synthesize ori-
ginal research data for each participant from all studies
that compare the same two treatments to address a speci-
fied clinical question. Although IPD meta-analyses may be
more time consuming and expensive than conventional
meta-analyses using aggregated data, they are considered
the gold standard approach for systematic reviews of inter-
ventions and are being published with increasing frequency
[1, 2]. They can improve clinical practice guidelines [3]
because they offer advantages over conventional meta-
analyses with respect to data quality and the type of
analyses that can be conducted. For example, in contrast to
aggregated data, the use of IPD allows investigation of
patient-level moderators, intention-to-treat analysis (when
data are available for all patients in randomized studies),
and application of appropriate multiple imputation tech-
niques to overcome issues related to missing data.
Network meta-analysis (NMA) allows the simultaneous
comparison of many relevant interventions, and there has
been an exponential increase in the number of NMAs
published in recent years [4]. Although NMA is com-
monly performed with aggregated data, the inclusion of
IPD can increase confidence in the results [5, 6], identify
interactions that are otherwise undetectable [1, 7–9], and
reduce variation in treatment effects both between studies
within pairwise comparisons (heterogeneity) and between
pairwise comparisons (inconsistency) by adjusting trial re-
sults for factors that may cause this variation [6]. The use
of IPD may also allow estimation of subgroup effects,
which in turn allows tailoring of results to patient charac-
teristics. Several investigators have recognized that the use
of IPD in NMAs may generate the most trustworthy evi-
dence to inform clinical decision making, and hence they
have been developing statistical methods to enhance IPD-
NMAs [5, 6, 10, 11]. The objective of this study is to con-
duct a comprehensive scoping review of the methods used
to perform indirect comparisons with IPD or IPD com-
bined with aggregated data. We also aim to review appli-
cations of indirect comparisons with IPD and summarize
network, methods and reporting characteristics.
Methods
This review was guided by the research questions: “What
are the existing methodologies available to apply an
IPD-NMA or an indirect comparison using IPD?" and
"What are the characteristics of the empirical networks
that include IPD (e.g., number of trials, patients, and
treatments)?”. A scoping review was applied for this
study based on the framework outlined by Arksey and
O’Malley [12] and using the Joanna Briggs Institute
methods manual [13]. We described the methods in de-
tail in our protocol publication [14].
Identifying relevant studies: data sources and search
strategy
We searched MEDLINE, Embase, the Cochrane Library,
and CINAHL from inception until the end of October
2014. No limits were placed on date of publication,
language, population, intervention, or outcome. The
search was carried out by an experienced librarian (Ms
Becky Skidmore), and a second librarian (Ms Heather
MacDonald) peer-reviewed the MEDLINE electronic
search strategy (see Additional file 1: Appendix 1) using
the Peer Review of Electronic Search Strategies (PRESS)
checklist [15]. Modified search strategies for remaining
databases are available upon request from the authors.
Grey literature sources (Google, Agency for Healthcare
Research and Quality, Canadian Medical Libraries List,
Medical Research Council, and National Health Service)
were searched, and references from included studies
were scanned.
Eligibility criteria
We included published papers, protocols, and abstracts,
as well as unpublished studies, that reported on a
method, application, or review of IPD indirect compari-
son methods involving studies of any design. Eligible
were application studies that compared the clinical ef-
fectiveness or safety of three or more interventions and
applied any type of indirect comparison, including ad-
justed indirect comparison, unadjusted indirect compari-
son, matching adjusted indirect comparison (MAIC),
simulated treatment comparison (STC), mixed compari-
son, and NMA. Studies including narrative comparisons
were excluded.
Several approaches have been suggested to conduct an
indirect comparison using IPD only or in combination
with aggregated data. The different types of IPD indirect
comparison methods identified in this scoping review
are outlined in Table 1. The adjusted indirect compari-
son, mixed comparison, and NMA approaches modeling
IPD can be categorized as one-stage and two-stage ap-
proaches. In one-stage methods, the IPD from all eligible
studies are analyzed within the same (usually linear)
model simultaneously, accounting for clustering of par-
ticipants within each study. Two-stage methods are used
to reduce IPD to aggregated data and then synthesize the
aggregated data from each study using an adjusted indir-
ect comparison, mixed comparison, or NMA model [16].
Study selection and data abstraction
Following a calibration exercise, two reviewers (AAV
and CS or MJE) independently screened each title and
abstract of the literature search results (level 1) and the
full-text of potentially relevant articles (level 2) using
Synthesi.SR [17]. Conflicts were resolved by discussion.
The final inter-rater agreement (across levels 1 and 2)
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between reviewers was 85 %. The same process was
followed for data extraction. When multiple publications
were identified for the same study, we abstracted data
from the most recent study (when the literature search
differed across studies) and considered the remaining
publications as companion reports, which were used for
supplementary material only. Details on the data
abstraction process can be found in Additional file 1:
Appendix 2.
Synthesis
Quantitative data from the retrieved networks with IPD
(e.g., number of patients, studies, and treatments in the
network) were summarized in terms of medians and
interquartile ranges (IQRs), and categorical data (e.g., ef-
fect measures, outcome data type, reference treatment
type) by frequencies and percentages. We compared
continuous network characteristics between different
methods using the Wilcoxon-Mann-Whitney test. All
tests were two-sided with a significance level of 0.05.
Results
The literature search yielded 201 potentially relevant ci-
tations, of which 91 unique citations met the eligibility
criteria based on title and abstract. Following review of
the corresponding full-text articles, 37 papers were eli-
gible for this review and included, along with 10 com-
panion reports (Fig. 1). All excluded citations and
reasons for exclusion are available in Additional file 1:
Appendix 3.
General characteristics of identified networks
We identified 23 (62 %) application articles [18–40], 11
(30 %) methodological articles [6, 41–49], 2 (5 %) re-
views of methods [50, 51], and 1 (3 %) protocol [52] for
an application article that has not yet been published
(Additional file 1: Appendix 4). The number of studies
with indirect comparison methods using IPD has in-
creased steeply since 2007 (Fig. 2). The IPD indirect
comparison methods were published in a wide variety of
journals, and most of the networks (17; 46 %) were
industry-sponsored. Further details can be found in
Additional file 1: Appendix 5.
Characteristics of identified methodologies
Summary of indirect comparison methodologies using IPD
A variety of indirect comparison methods using IPD
were identified (Table 2). Twenty-four IPD-NMA (73 %)
and 9 MAIC (27 %) approaches were applied in total in
the empirical studies. The first IPD-NMA study, pub-
lished in 2007, applied a meta-regression model for
time-to-event data [19]. About half of the networks (17;
52 %) applied a Bayesian hierarchical model, whereas the
Table 1 Individual patient data indirect comparison methods
• Adjusted indirect comparison: The method derives an indirect estimate
for the relative effectiveness or safety of two different treatments
adjusted by comparing the results of their direct comparisons (i.e.
pairwise meta-analyses) with a common comparator treatment [68].
Consider, for example, a tree-shaped triangular network composed by
some IPD (or IPD and aggregated data) studies comparing treatment A
against treatment B, and some studies comparing treatment A against
treatment C. The method uses the summary treatment effect estimates
derived by a pairwise meta-analysis (which can be a one-stage or
two-stage approach) for studies Avs.B and for studies Avs.C.
• Matching adjusted indirect comparison (MAIC): The method estimates an
indirect comparison of the treatments of interest [48]. Consider the tree-
shaped triangular network ABC composed by some IPD studies comparing
Avs.B treatments and some aggregated data studies comparing Avs.C
treatments. The method uses the information from the IPD trials on one
treatment arm (B) and the information from the aggregated data trials
on the other treatment of interest (C). The patient characteristics from the
IPD trials on treatment B are then matched to the ones of the aggregated
data trials on treatment C using an approach similar to propensity score
weighting. Specifically, the patient baseline characteristics in IPD trials and
treatment B are reweighted so that the weighted average of the patient
characteristics matches the characteristics of the population in treatment
C of the aggregated data trials. The weights are modeled as a linear
combination of all reported baseline characteristics. After matching
the baseline characteristics between the two groups, the treatment
outcomes are compared across the trial populations using the adjusted
mean for treatment B and observed mean for treatment C.
• Simulated treatment comparison (STC): A similar approach to the MAIC is
the STC, which uses a different process to adjust for population character-
istics [49]. Considering the same tree-shaped ABC network, the STC
method estimates the treatment response in B using information from
the IPD trials and a predictive regression model with patient-level
characteristic covariates. Then a statistical calibration of the trial(s) with
IPD is performed to match the characteristics with aggregated data trials
and treatment C. Trial data are simulated for treatment B based on the
statistical calibration. The adjusted mean for treatment B is compared
with the observed mean for treatment C. The MAIC and STC methods
may be particularly useful when there is insufficient data from head-to-
head comparison trials, and when there is insufficient data to apply an
adjusted indirect comparison (e.g., disconnected network of trials) [50].
• Network meta-analysis (NMA) approaches: When both direct and indirect
evidence (IPD or in combination with aggregated data or aggregated
data only) are available for the same comparison (e.g., Bvs.C), then these
may be combined in a mixed effect size using the mixed comparison
method [69]. The mixed comparison estimate is a weighted average of the
meta-analytic effect estimate Bvs.C and the adjusted indirect comparison
for Bvs.C. A suggested approach for combining direct and indirect evidence
using the mixed comparison method is the inverse variance method with
weights the inverse of the variance of the estimated effects. An approach
to simultaneously compare multiple treatments in a single analysis is by
using a meta-regression model [70]. Each study-specific treatment effect is
expressed as a linear function of the basic parameters, which is a set of
comparisons of the treatments in the network versus the reference
treatment. Assuming A is the reference treatment then Avs.B and Avs.C are
the basic parameters for the ABC network. This approach uses the different
treatment comparisons as covariates in the meta-regression model. In
particular, it uses dummy variables for the basic parameters to define the
basic contrasts Avs.B and Avs.C, omits the intercept, and specifies the
covariate values so that consistency between direct and indirect evidence
holds. An alternative way to apply a NMA is by using hierarchical models
[71]. Studies have shown that the majority of NMA applications have been
carried out in a Bayesian setting using hierarchical models [4, 10, 42].
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second most frequently used method was the MAIC ap-
proach (8; 24 %) (Fig. 3).
Most IPD-NMAs involved one- or two-stage ap-
proaches (see Additional file 1: Appendix 4 and Add-
itional file 2). Several one-stage Bayesian hierarchical
models were discussed across the methodological pa-
pers, including either IPD alone [6, 41–43] or a mixture
of IPD and aggregated data [41, 42, 44, 45] (see Table 3).
For IPD alone, three studies [6, 10, 41] presented models
for dichotomous outcome data using the odds ratio, and
a fourth study [43] proposed a model for multiple con-
tinuous outcomes using the mean difference. For com-
bining IPD with aggregated data, three studies [41, 42]
presented models for dichotomous outcome data using
the odds ratio, a fourth study [44] proposed a model for
time-to-event data using the hazard ratio, and a fifth
study [45] suggested a model for continuous data using
the mean difference. All of the aforementioned models
were developed to model randomized clinical trials
(RCTs), apart from the models suggested by Saramago
and colleagues [10], which can combine cluster- and
patient-randomized trials, and the approach proposed by
Thom and colleagues [45], which models RCTs and
single-arm observational trials.
The majority (15; 63 %) of the 24 empirical IPD-
NMAs used a one-stage analysis; two-stage analysis was
the second most frequent method (7, 29 %), one study
(4 %) used IPD as an informative prior [32], and one
study (4 %) [33] was unclear about the analysis format.
Among the 33 networks, 16 (52 %) implemented indirect
comparison methods modeling IPD in Bayesian statistics
software (JAGS [1; 3 %] [53] OpenBUGS [2; 6 %] [54]
WinBUGS [14; 43 %] [55] (Table 4). Of the total 37 pa-
pers, only three (8 %) IPD-NMAs [10, 44, 45] provided
their code in the manuscript, whereas one (3 %) re-
ported that the code is available upon request [31]. Of
the 24 empirical IPD-NMAs, 9 (38 %) used IPD only, 13
(54 %) used a mixture of IPD and aggregated data, and
two (8 %) applied a combination of methods using both
IPD alone and a mixture of IPD and aggregated data.
The data format used in all MAICs was a mixture of
IPD and aggregated data. The design of the studies in-
cluded in all of the empirical networks was an RCT,
except for in three studies (9 %), which included non-
randomized data [10, 31, 45]. The reasons for the
choice between IPD or their combination with aggre-
gated data included the following: (not) having access to
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Fig. 1 PRISMA flow chart for study selection. IPD-NMA = individual patient data network meta-analysis
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research group, to use IPD as a prior distribution in
the analysis, to assess the benefits of acquiring IPD
for a subset of trials, to compare IPD-NMA models
with aggregated NMA models, and to apply a MAIC
(Additional file 2).
Key methodological components of indirect comparison
methods with IPD
Of the 22 empirical IPD-NMAs that reported which
model was selected among fixed and random-effects, 10
(45 %) employed a random-effects model, 7 (32 %) ap-
plied a fixed-effect model, and 5 (23 %) used both ap-
proaches. All but two of the Bayesian random-effects
IPD-NMA models [10, 32] used a non-informative prior
for the between-study variance parameter. Many net-
works applied various modeling approaches, which
were most frequently compared using the deviance
information criterion (13; 40 %). The rank order effect-
iveness or safety of treatments per network was assessed
in 11 (33 %) empirical studies using the probability of being
the best. Several authors identified differences in the results,
when both IPD methods and aggregated data approaches
were applied, such as differences in the consistency
evaluation, precision in treatment effects, and significance
of treatment effect modifier (Additional file 2).
The majority (26; 79 %) of the 33 empirical studies did
not report whether an approach had been applied to
handle missing data. The approach most commonly ap-
plied to follow the intention-to-treat principle in the
identified indirect comparison methods was the last
observation carried forward (4; 12 %), where missing
values are replaced with the last observed measurement.
Thirteen (68 %) of the 19 full IPD-NMAs assessed in-
consistency, but only 5 (38 %) of these used statistical
approaches for this evaluation. One of the full networks
was composed of one closed loop of multi-arm studies,
and consistency could not be evaluated because of inher-
ent correlations [27]. Of the 13 IPD-NMAs that assessed
the consistency assumption, 5 (38 %) detected inconsist-
ency in their network and used IPD to adjust for differ-
ences in effect modifiers across treatment comparisons.
Among the nine networks that included different
treatment doses, the relationship between treatment
and dose was ignored either by lumping (5; 56 %) or
splitting (4; 44 %) the doses as if they were different
treatments.
Fig. 2 Bar plot of the indirect methods using individual patient data (IPD) by year, method, and type of network. The frequencies of the identified
methods (n = 33) were 17 (52 %) Bayesian hierarchical models†, 2 (6 %) Bucher methods‡, 8 (24 %) matching adjusted indirect comparisons (MAIC)#,
1 (3 %) extended MAIC#, 4 (12 %) meta-regression models*, 1 (3 %) mixed comparison**.
†Bayesian hierarchical models are multi-level models presented as a generalization of regression methods. Different levels account for the
variation in patients between and within studies which form the hierarchical model. Network meta-analyses conducted in a Bayesian framework
express the observed treatment effects via their ‘true’ underlying treatment effects. ‡The Bucher method (or adjusted indirect comparison) is
the statistical approach to derive an indirect treatment effect estimate for two competing treatments that have been compared with a common
intervention [68]. #Matching-adjusted indirect comparisons are indirect comparisons that use IPD from the active treatment trial(s) and aggregate data
(AD) from the comparator treatment trial(s). The patient characteristics from the IPD trial(s) are weighted a priori and matched with the characteristics
of the population in the AD trial(s) so that the baseline characteristics are similar between the two treatment groups. A recent extension of the method
accounts for differences in endpoint definitions and missing data [46]. *A linear (or meta-regression) model with dummy variables reflecting the basic
parameters (comparisons of all treatments vs. a common comparator), and with regression coefficients the NMA treatment effect estimates [69].
Under the consistency assumption, all treatment comparisons are written as functions of the basic parameters. **A mixed comparison between two
treatments is the weighted average of direct and indirect estimates for the same treatment comparison, with weights the inverse of the variance of
the estimated effects [69]
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Methods used to report results in the identified networks
The methods used to report the summary estimates from
the analyses varied across the papers. Almost half of the
empirical studies (15; 45 %) included a network diagram
in the results section or in supplementary material. Tables
(14; 42 %) and forest plots (27; 82 %) were the most com-
mon methods of reporting the results of indirect compari-
son methods (Additional file 1: Appendix 6).
Characteristics of empirical studies
Protocol and rationale for using IPD
The 33 studies with empirical indirect comparison
methods using IPD, included 23 application articles
[18–40], 8 methodological articles with empirical exam-
ples [6, 10, 42–46, 48], 1 review [51], and 1 protocol [52]
(Additional file 1: Appendix 6). Of these 33 studies, 9
(27 %) IPD-NMAs reported the existence of a study
protocol; an additional 3 (9 %) studies (two IPD-
NMAs and one MAIC) mentioned that protocols existed
[20, 33, 44], but references were not provided, and we
were unable to locate them. None of the eight metho-
dological articles cited a study protocol, but 4 of them
provided a reference of the original publication of the em-
pirical dataset, which cited a protocol. Around 3 to 4 years
were required to publish the final IPD review after the
protocol was published (Additional file 2). We identified
22 (67 %) studies in which investigators had access to IPD
through a collaborative research group, whereas 9 (27 %)
systematic reviews used several methods to contact the
original authors and collect IPD. Six studies reported the
proportion of contacted authors who provided IPD, and
the median proportion of studies that obtained IPD was
68 % (IQR 58–78 %). No IPD review reported reasons for
any non-located IPD studies. Our response rate to










MAIC [48] STC [49]
No. of empirical studies applying
method (n = 33)
2 (6 %) [20, 52] 1 (3 %) [28] 4 (12 %)
[19, 21, 25, 26]
17 (52 %) [6, 10, 18, 22–24,
27, 29–33, 42–45, 51]
8 (24 %) MAICs
[34–38, 48, 57] and




1-stage or 2-stage process 2-stage 2-stage Both can be
applied
Both can be applied NA NA




IPD+AD/IPD only IPD+AD IPD+AD
Avoids selective use of indirect
evidence from a network of trials
No No Yes Yes No No
Can compare >2 treatments at
a time for efficacy/safety
No No Yes Yes No No
Preserves within-trial randomization Yes Yes Yes Yes No No
Study-specific true treatment effects
can be assumed as fixed or random
with common mean effect for each
pairwise comparison
Yes Yes Yes Yes No No
May account for potential clinical
and methodological differences
across trials
Yes Yes Yes Yes No No
Does not require assessment for
transitivity assumption
No No No No Yes Yes
Mean treatment effects expressed
via consistency equations
No Yes Yes Yes No No
Can rank all competing treatments
for same condition
No No Yes Yes No No
Enables adjustment for predefined
set of patient characteristics
No No Yes Yes Yes Yes
Can be applied even in disconnected
network of trials
No No No No Yes Yes
AD aggregated data, IPD individual patient data, MAIC matching adjusted indirect comparison, NA not applicable, NMA network meta-analysis, STC simulated
treatment comparison
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requests for additional information for 29 papers was
82 % (14/17 authors; some authors were contacted for
more than one paper).
Many of the papers reported the rationale for using
IPD instead of aggregated data (26; 79 %); these reasons
included adjusting for potential confounding factors
[4, 6, 21, 23, 29, 30, 32, 34, 42, 48, 56], exploring rea-
sons for heterogeneity and/or inconsistency [6, 10, 20,
23, 31, 42], increasing power to detect treatment effect
modifiers [10, 19, 45], overcoming bias (e.g., aggregation
Table 3 Bayesian hierarchical IPD-NMA models described in the identified methodological articles
Model 1-stage or
2-stage process




1-stage IPD only RCTs Dichotomous Odds ratio No interactions; exchangeable
treatment by covariate interactions;






RCTs Dichotomous Odds ratio No interactions; independent treatment
by covariate interactions; exchangeable
treatment by covariate interactions;
common treatment by covariate
interactions
Hong et al. [43] 1-stage IPD only RCTs Continuous Mean
difference
Exchangeable treatment by covariate
interactions
Jansen [41] 1-stage IPD+AD and
IPD only
RCTs Dichotomous Odds ratio Exchangeable treatment by covariate








Dichotomous Odds ratio Independent treatment by covariate
interactions; exchangeable treatment
by covariate interactions; common
treatment by covariate interactions
Saramago
et al. [44]
1-stage IPD+AD RCTs Time-to-
event








Independent treatment by covariate
interactions
AD aggregated data, IPD individual patient data, IPD-NMA individual patient data network meta-analysis, RCT randomized controlled trial
Fig. 3 Bubble plot of indirect methods using individual patient data by year of publication and discipline. The size of each bubble is proportional
to the number of studies published in the corresponding year and discipline. Light grey bubbles represent publications using the matching adjusted
indirect comparison (MAIC) and simulated treatment comparison (STC) methods, white bubbles represent publications using an individual patient data
network meta-analysis (IPD-NMA) method, and dark grey bubbles represent publications using both IPD-NMAs and MAIC/STC methods
Veroniki et al. BMC Medical Research Methodology  (2016) 16:47 Page 7 of 14
Table 4 Methodological characteristics of identified empirical networks, including unpublished data provided by study authors.
Figures are no. (%) of studies
Characteristic IPD-NMA studiesa MAIC studiesa Totala
Design of studies included in analyses
RCTs 21 (70) 9 (30) 30 (91)
RCTs + observational 1 (100) 0 (0) 1 (3)
RCTs + quasi-RCTs 1 (100) 0 (0) 1 (3)
RCTs, non-RCTs, CBA 1 (100) 0 (0) 1 (3)
Total 24 (73) 9 (27) 33 (100)
Fixed- or random-effects model
Random-effects model 10 (100) 0 (0) 10 (30)
Fixed-effect model 7 (100) 0 (0) 7 (21)
Fixed- and random-effects models 5 (100) 0 (0) 5 (15)
Not reported/not applicable 2 (18) 9 (82) 11 (33)
Total 24 (73) 9 (27) 33 (100)
Between-study variance estimator/prior
Non-informative prior 10 (100) 0 (0) 10 (67)
Informative prior 1 (100) 0 (0) 1 (7)
Minimally informative prior 1 (100) 0 (0) 1 (7)
DL [72] 1 (100) 0 (0) 1 (7)
REML [73] 1 (100) 0 (0) 1 (7)
Not reported 1 (100) 0 (0) 1 (7)
Total 15 (100) 0 (0) 15 (100)
Methods used to compare different models
DIC [74] 10 (100) 0 (0) 10 (30)
Statistical significance of regression coefficients
and between-study variance
3 (100) 0 (0) 3 (9)
DIC and residual deviance [74] 2 (100) 0 (0) 2 (6)
Comparison of point estimates and their CIs 0 (0) 2 (100) 2 (6)
AIC and Hosmer–Lemeshow [75, 76] 0 (0) 1 (100) 1 (3)
DIC and AIC [74, 75] 1 (100) 0 (0) 1 (3)
Not applicable 8 (57) 6 (43) 14 (42)
Total 24 (73) 9 (27) 33 (100)
Statistical techniques used for missing participant data
LOCF 2 (67) 1 (33) 3 (9)
MCMC multiple imputations 2 (100) 0 (0) 2 (6)
ACA 1 (100) 0 (0) 1 (3)
LOCF and ACA 0 (0) 1 (100) 1 (3)
Not reported/unclear 19 (73) 7 (27) 26 (79)
Total 24 (73) 9 (27) 33 (100)
Methods used to rank treatment effectiveness/safety
Probability of being the best 11 (100) 0 (0) 11 (33)
Not reported/not applicable 13 (59) 9 (41) 22 (67)
Total 24 (73) 9 (27) 33 (100)
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bias) [10, 43], producing more precise estimates of
treatment effect (even in the absence of treatment-by-
covariate interactions) [19, 44], adjusting for differences
in patient-level characteristics even when a small number
of studies (<10) was available [35, 37, 10], increasing
power due to rare events [18], and matching differences in
baseline characteristics [35–38, 57]. One of the identified
simulation studies evaluated the advantages of including
IPD in NMA [5]. In that study, Jansen [5] evaluated the
performance of tree-shaped triangular IPD-NMAs model-
ing a combination of IPD and aggregated data compared
with NMAs using aggregated data and showed that an
IPD-NMA can considerably reduce bias and increase
precision of treatment effect estimates when there is an
imbalance in patient-level treatment effect modifiers
across comparisons.
Table 4 Methodological characteristics of identified empirical networks, including unpublished data provided by study authors.
Figures are no. (%) of studies (Continued)
Assessment of consistency assumption
Yes 13 (100) 0 (0) 13 (39)
No/unclear 6 (75) 2 (25) 8 (24)
Not applicable 5 (42) 7 (58) 12 (36)
Total 24 (73) 9 (27) 33 (100)
Methods used to assess consistency assumption
Informal approachesb 8 (100) 0 (0) 8 (62)
Loop-specific approach [68, 77] 1 (100) 0 (0) 1 (8)
Loop-specific approach and back-calculation [68, 77, 78] 1 (100) 0 (0) 1 (8)
Lu and Ades [79] 1 (100) 0 (0) 1 (8)
Lumley [70] 1 (100) 0 (0) 1 (8)
Node-splitting [78] 1 (100) 0 (0) 1 (8)
Total 13 (100) 0 (0) 13 (100)
Inclusion of different treatment doses
No 18 (75) 6 (25) 24 (73)
Yes 6 (67) 3 (33) 9 (27)
Total 24 (73) 9 (27) 33 (100)
Approaches used to account for different treatment doses
Lumping doses 4 (80) 1 (20) 5 (56)
Splitting doses 2 (50) 2 (50) 4 (44)
Total 6 (67) 3 (33) 9 (100)
Software
WinBUGS [55] 7 (100) 0 (0) 7 (21)
SAS [80] 2 (33) 4 (67) 6 (18)
WinBUGS and R [55, 81] 5 (100) 0 (0) 5 (15)
OpenBUGS [54] 2 (100) 0 (0) 2 (6)
WinBUGS and Stata [55, 82] 2 (100) 0 (0) 2 (6)
JAGS and R [53, 81] 1 (100) 0 (0) 1 (3)
Stata [82] 1 (100) 0 (0) 1 (3)
Not reported 4 (44) 5 (56) 9 (27)
Total 24 (73) 9 (27) 33 (100)
ACA available case analysis, AIC Akaike information criterion, CBA controlled before-and-after, CI confidence interval, DIC deviance information criterion, DL
DerSimonian and Laird, IPD-NMA individual patient data network meta-analysis, LOCF last observation carried forward, MAIC matching adjusted indirect
comparison, MCMC Markov chain Monte Carlo, RCT randomized clinical trial, REML restricted maximum likelihood
aPercentages were calculated across the row for IPD-NMA and MAIC/STC, but down the column for the “Total” column. Total number of included studies n = 37.
Total number of empirical networks n = 33. Please note that the empirical networks include 8 methodological and 1 review papers
bInformal approaches are comparison of NMA results with results previously published, comparison of NMA results with pairwise meta-analysis results, comparison
of IPD-NMA with meta-regression IPD-NMA results, comparison of IPD-NMA with aggregated data NMA results
Veroniki et al. BMC Medical Research Methodology  (2016) 16:47 Page 9 of 14
Primary outcome and competing treatments
The primary outcome was an effectiveness outcome in
31 (94 %) studies and was categorized as objective in 26
(79 %) networks. The median number of outcomes
assessed in the eligible networks was one (IQR 1-3)
(Additional file 1: Appendix 4 and Appendix 6). About
half of the networks (17; 52 %) reported a dichotomous
primary outcome, and nine (27 %) included a continuous
primary outcome (see Additional file 1: Appendix 6). The
empirical networks evaluated a wide range of interventions,
pharmacological versus placebo or control being the most
common type of intervention comparison (17; 52 %). The
median number of participants in the empirical networks
was 899 (IQR 310–1735) (for IPD-NMAs, 1342 [IQR 493–
2567]; for MAICs, 329 [IQR 221–601]; P = 0.024).
Size and geometry of the identified networks
We identified 33 empirical networks: 21 (64 %) full
networks and 12 (36 %) tree-shaped networks. In
Additional file 1: Appendix 7 and Appendix 8 we present
the distribution of trials, treatment groups, and patients
for each network, shown separately for IPD-NMA and
MAIC approaches. The median number of interventions
assessed per network was 5 (IQR 3–6) (for IPD-NMAs, 6
[IQR 5–7]; for MAICs, 3 [IQR 3–4]; P = 0.003), and the
median number of closed loops in full networks was 1
(IQR 0–4) (for IPD-NMAs, 2 [IQR 1–5]; for MAICs, 0
[IQR 0-0]; P = 0.002). Most IPD-NMAs (19; 79 %) were
applied to full networks (including 13 Bayesian hierarch-
ical models, four meta-regression models, one adjusted in-
direct comparison, one mixed comparison), whereas most
MAIC (7; 78 %) were used for tree-shaped networks.
The median number of trials included per network
was 10 (IQR 4–19) (for IPD-NMAs, 15 [IQR 8–20]; for
MAICs, 2 [IQR 3–5]; P <0.001), and the median number
of IPD trials included in a network was 3 (IQR 1–9) (for
IPD-NMAs, 6 [IQR 2–11]; for MAICs, 2 [IQR 1–2]; P =
0.007). Full networks had a median number of multi-
arm studies of 0 [IQR 0–2] (for IPD-NMAs, 0 [IQR 0–
3]; for MAICs, 0 [IQR 0-0]; P = 0.251). The median
number of patients in a network was 3874 (IQR 1162–
9830) (for IPD-NMAs, 5310 [IQR 3290–14750]; for
MAICs, 997 [IQR 520–1264]; P <0.001), and the median
number of patients in IPD trials was 1790 (IQR 599–5110)
(for IPD-NMAs, 3848 [IQR 1444–5643]; for MAICs, 541
[IQR 350–625]; P = 0.007). No application papers using the
STC method were identified.
Discussion
Recommendations to authors
This study is the first scoping review to provide a com-
prehensive overview of the methods for completing indir-
ect comparison analyses using IPD. It also describes the
methodological and reporting characteristics of empirical
networks in healthcare, which will help not only in the de-
sign of future simulation studies, but also in refining the
preferred reporting items for systematic reviews and
meta-analyses (PRISMA) using IPD [58] and developing
the PRISMA for IPD-NMAs. This review showed that
essential methodological and reporting items suggested to
be included by PRISMA-IPD [58] and PRISMA-NMA
[59], such as evaluation of the consistency assumption, ex-
istence of a study protocol, and methods used to request,
collect, and manage IPD, were poorly reported in IPD in-
direct comparisons. An IPD indirect comparison review
should be clearly reported in line with the International
Society for Pharmacoeconomics and Outcomes Research
(ISPOR), PRISMA-IPD and PRISMA-NMA tools [58–60].
However, given that these guidelines are not specific to
IPD indirect comparison methods, we outline some add-
itional information that we suggest be reported in IPD
indirect comparisons to improve transparency in Table 5
[58–60]. For example, the rationale for the choice of IPD
indirect comparison method should be provided, since dif-
ferent approaches are associated with different properties,
and hence they may lead to different and potentially con-
flicting results.
Comparison with existing evidence
The IPD indirect comparisons are only a minority of the
aggregated data indirect comparisons, which is also true
for IPD meta-analyses compared to aggregated data meta-
analyses [2]. Our review showed that a variety of methods
are used to synthesize evidence from networks of trials,
including both IPD-NMAs and MAIC approaches. Indir-
ect comparison methods using IPD have been used in a
wide range of clinical disciplines, as have NMAs modeling
aggregated data [61, 62]. The majority of the IPD net-
works applied Bayesian hierarchical models, which is also
preferred in NMAs with aggregated data [4, 63]. Similar
to IPD meta-analyses [2], one-stage analyses dominated
among the statistical approaches. For IPD alone or in
Table 5 Suggested information to report in an individual
patient data indirect comparison to supplement ISPOR,
PRISMA-IPD and PRISMA-NMA
• Rationale for the IPD indirect comparison method selected.
• Timelines to obtain, clean, and analyze data.
• Process to identify IPD studies, and if authors were contacted, which
methods were used to contact them, how many reminders were sent,
and who requested the IPD.
• Whether the obtained IPD were anonymized.
• Mechanism and strategy for storage of IPD.
• Whether IPD were requested from all studies or just a subset of
studies; report reasons for all missing IPD studies.
• Potential legal agreements to access IPD and difficulties encountered
due to data protection and intellectual property issues.
• Estimator or prior for the between-study variance and rationale for this
selection, when a random-effects model is applied.
• Software in which the indirect comparison was performed and the
statistical code used.
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combination with aggregated data, models have been de-
veloped for dichotomous and continuous outcomes,
whereas for the combination of IPD with aggregated data,
models also exist for time-to-event data. However, the
statistical code is only rarely available to the reader, which
was also observed by Sobieraj et al. [61] in NMAs with ag-
gregated data. In agreement with aggregated data NMAs
[4, 62], most IPD networks included at least one closed
loop. Although the identified IPD-NMAs have been re-
cently published and IPD can be used to assess and adjust
for differences in effect modifiers across treatment compar-
isons avoiding aggregation bias, our findings on consistency
agree with findings on aggregated data NMAs [4, 64, 65].
For a review of methods to assess the consistency assump-
tion with an application to an empirical IPD-NMA, we en-
courage the readers to consult Donegan et al. [66].
Consistent with aggregated NMAs [62], almost half of
the 33 empirical IPD indirect comparisons included a net-
work diagram. Among the 33 identified empirical networks,
the typical IPD network had a dichotomous, objective pri-
mary outcome, compared pharmacological and placebo/
control interventions, and involved five interventions and
ten trials. Nikolakopoulou et al. [4] indicated that the typ-
ical network with aggregated data had a dichotomous,
semi-objective primary outcome, compared pharmaco-
logical and placebo/control interventions, involved six in-
terventions, and was informed by 21 trials in their scoping
review. This difference may be because the conduct of an
IPD indirect comparison is resource-intensive and because
IPD allows the assessment of more targeted clinical ques-
tions, where fewer studies are available. In the retrieved
IPD indirect comparisons, no study reported reasons for
missing or incomplete IPD, which was also underreported
in IPD reviews for meta-analyses [2]. In contrast to NMAs
modeling aggregated data, half of the IPD studies were
industry-sponsored (27 % vs. 46 %) [61].
One in three empirical approaches used the MAIC
method to model IPD. In contrast to IPD-NMAs, both
MAIC and STC provide more targeted comparison
results, and consider the outcomes observed in the treat-
ments of interest directly. As such, these methods pro-
duce a comparison of outcomes based on two specific
arms of the available trials reflecting what may have
been observed if the treatments had come from the
same randomized trial, whereas the remaining treatment
comparators involved in the network of trials are ana-
lyzed alongside the selected treatments of interest. The
advantage of MAIC and STC methods is that they may
be used when NMA is impossible, serving as an alterna-
tive approach to NMA. However, caution is needed, as
these methods are based on the assumption that the
studies should have the same clinical characteristics and
they do not account for reasons for potential differences
across trials examining the treatments of interest.
Limitations
One limitation of our study is our focus on the presentation
and description of methods, characteristics, and reporting
of indirect comparison methods with IPD without assess-
ment of the quality of included papers or the methods
themselves. However, scoping reviews typically do not in-
clude assessment of the risk of bias [13]. Another limitation
is our reliance on information reported in the identified ar-
ticles; as such, we may have missed important methods that
were omitted from the authors’ reports, even if these were
appropriately applied in their studies. For example, in the
33 empirical networks we included eight methodological
articles and one review with empirical examples, where key
reporting items may be missing due to space constraints.
An additional limitation is that we may not have retrieved
all indirect comparison methods with IPD, as some studies
may not have been indexed using the search terms we
used. However, we believe that our sample is representa-
tive of the indirect comparison methods applied in the
medical literature, and most of our results are comparable
with previous reviews of NMAs using aggregated data, as
well as with the results of scoping reviews on IPD meta-
analyses.
Previous scoping reviews of NMAs have also shown
inadequate reporting [4, 61, 64, 67]. Hence, it is impera-
tive that guidelines are developed to improve the quality
of reporting in IPD-NMAs. Further research is also needed
to assess the properties and performance of the various
indirect comparison methods modeling IPD.
Conclusions
This is the first scoping review that we are aware of
focusing on methods for performing indirect comparisons
with IPD, describing also the methodological and re-
porting characteristics of empirical networks in health-
care. To date, one in three approaches used to model IPD
in connected networks of evidence disregarded patient
randomization and between-study heterogeneity, consid-
ering only information from treatments of interest as if
they had come from the same randomized trial. Key meth-
odological and reporting elements (e.g., evaluation of the
consistency assumption, existence of a study protocol) were
frequently missing, even for networks of trials published in
high impact journals. The impact of failing to consider and
report important methodological aspects may result in er-
roneous clinical decisions. It is of paramount importance
that reporting of IPD-NMAs is improved and that investi-
gators are aware of the properties of the various indirect
methods using IPD before applying them.
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